Melissa Hardesty, MD, MPH, Discusses the Focus of the 2021 Society of Gynecologic Oncology Annual Meeting

Article

Hardesty detailed her expectations for the focus of the conference and the exciting topical opportunities presented this year’s SGO Annual Meeting compared with past years.

Melissa Hardesty, MD, MPH, of the Alaska Women’s Cancer Care, spoke with CancerNetwork® regarding topics of discussion at the forefront of this year’s Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer.

Transcription:

This year, the meeting has focused on diversity and inclusiveness [by] really looking at some actual research about how these things impact our patients, how they impact our providers, racial bias, and all of that. There’s a lot of content that’s specifically trying to help us learn how to do better in these ways, to just continue on further conversations. I know that the program organizers have put a strong emphasis on that. There [are] exciting talks in the opening plenary that I think in meetings past might not have been selected for [presentation, and] focusing on the commitment to that area.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content